Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.59 |
| ▸ | PGD | P52209 | 3/20 | 0.49 |
| ▸ | PGK1 | P00558 | 1/20 | 0.44 |
| ▸ | PGK2 | P07205 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849450 | 1.00 | MPI (0.59) | MPIPGDPGK1PGK2S1PR1 | |
| SCHEMBL19393 | 1.00 | MPI (0.59) | MPIPGDPGK1PGK2S1PR1 | |
| SCHEMBL158926 | 1.00 | MPI (0.59) | MPIPGDPGK1PGK2S1PR1 | |
| SCHEMBL20718807 | 1.00 | MPI (0.59) | MPIPGDPGK1PGK2S1PR1 | |
| SCHEMBL23787745 | 0.89 | MPI (0.49) | MPIPGDPGK1PGK2S1PR1 | |
| SCHEMBL9078417 | 0.87 | MPI (0.45) | MPIPGD | |
| SCHEMBL2851628 | 0.86 | MPI (0.43) | MPIPGDPGK1PGK2 | |
| SCHEMBL2851632 | 0.84 | MPI (0.41) | MPIPGD | |
| SCHEMBL9937657 | 0.84 | MPI (0.49) | MPIPGDPGK1PGK2S1PR1 | |
| SCHEMBL2851638 | 0.84 | MPI (0.41) | MPIPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006006757-A1 | COMPOSITION FOR LOWERING BLOOD GLUCOSE COMPRISING HEXOSE MONOPHOSPHATE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-01-19 | — | — | WO | claimed |
| US-20240293555-A1 | CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | CEDARS-SINAI MEDICAL CENTER | 2024-09-05 | — | — | US | disclosed |
| WO-2012027797-A1 | ANTI-INFLAMMATORY COMPOSTION | JAMES DAVID CHARLES (AU) | 2012-03-08 | — | — | WO | disclosed |
| US-20110099668-A1 | Expressing GLK in plants | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF AGRICULTURE AND AGRI-FOOD (CA) | 2011-04-28 | — | — | US | disclosed |
| US-20100324123-A1 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | YALE UNIVERSITY (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2061480-A2 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | YALE UNIVERSITY (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008076156-A2 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | YALE UNIVERSITY (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1887081-A2 | DNA Sequences | Ceres Incorporated (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006006757-A1 | COMPOSITION FOR LOWERING BLOOD GLUCOSE COMPRISING HEXOSE MONOPHOSPHATE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-01-19 | — | — | WO | disclosed |
| EP-1586645-A2 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | Ceres Incorporated (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20020061301-A1 | HUMAN CARBOHYDRATE METABOLISM ENZYMES | INCYTE PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| EP-1059354-A2 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | Ceres Incorporated (US) | 2000-12-13 | — | — | EP | disclosed |
| EP-1033405-A2 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | Ceres Incorporated (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-0653438-A2 | Oligonucleotide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293555-A1 | CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | CSGALNACT1, SLC2A8, FUT6 | MPI 38/4885PGD 793/4885PGK1 1183/4885 |
| US-20100324123-A1 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | GLMN, RNGTT, GMPS | MPI 1155/4885PGD 371/4885PGK1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.